Westra Tjalke A, Daemen Toos, Postma Maarten J, Wilschut Jan C
Universitair Medisch Centrum Groningen, afd. Medische Microbiologie, sectie Moleculaire Virologie, Groningen, The Netherlands.
Ned Tijdschr Geneeskd. 2009;153:A356.
Up to now the turnout for the human papillomavirus (HPV) vaccination programme implemented this year in the Netherlands has been lower than expected. This may be the result of negative publicity and doubts about the efficacy of the vaccination programme. To provide some clarity about the efficacy, this article gives an overview of the cost effectiveness analyses carried out on the introduction of HPV vaccination in the Netherlands. These studies have shown that vaccination of a cohort of 12-year-old girls using the HPV vaccine may ultimately prevent per year 217-421 cases of cervical cancer and 93-173 deaths caused by this disease in the Netherlands. It has also been shown that HPV vaccination is a cost effective strategy and that about 1000 girls must be vaccinated to prevent 1 death. The actual health benefits gained by HPV vaccination are strongly dependent on vaccination coverage. It is therefore important that this remains high (85-100%).
到目前为止，荷兰今年实施的人乳头瘤病毒（HPV）疫苗接种计划的参与率低于预期。这可能是负面宣传以及对疫苗接种计划有效性的怀疑导致的结果。为了对有效性有更清晰的认识，本文概述了在荷兰引入HPV疫苗接种所进行的成本效益分析。这些研究表明，在荷兰，使用HPV疫苗为一群12岁女孩接种疫苗，每年最终可能预防217 - 421例宫颈癌以及93 - 173例由该疾病导致的死亡。研究还表明，HPV疫苗接种是一种具有成本效益的策略，大约必须为1000名女孩接种疫苗才能预防1例死亡。HPV疫苗接种实际获得的健康益处很大程度上取决于疫苗接种覆盖率。因此，保持高覆盖率（85% - 100%）很重要。
